As the Vice President and Head of 澳门葡京赌博游戏 Clinical Operations, I lead a diverse organisation of over 2700 employees across 45 countries, responsible for the strategic and operational delivery of hundreds of clinical trials from Phase 1 to 3. I have over 25 years of experience in the pharmaceutical industry across all phases of development and in a broad range of therapy areas.
My team works in strategic partnership with our therapy area teams to translate drug development strategy into action, from study design to regulatory submission. We deliver our work using our own internal delivery engine and through partnerships with Clinical Research Organisations, 确保有效的, 道德, and high-quality 澳门葡京网赌游戏 clinical trials and programmes. There are many interrelated and co-dependent disciplines within 澳门葡京赌博游戏 clinical 操作, including early and late phase programme and study management for CVRM, R&I和V&I, and other expert groups that support across 澳门葡京赌博游戏 and 肿瘤学, 包括现场管理 & 监测、临床资料 & insights, global clinical solutions, process, quality & business capability, alliance management, and business planning & 操作. All these functions work together to plan and deliver clinical programmes and trials on time, 预算, 而且品质卓越.
A recent focus of our team has been the implementation of new digital technologies to enable remote data collection through devices like wearables and sensors. 除了, we are looking for new ways to conduct clinical trials that improve our patients’ experience. This work accelerated during COVID-19 to enable the continuation of our clinical trial programs, and continues today to ensure we deliver more new medicines to patients.
Since joining 澳门葡京网赌游戏 in 2013, I have had the opportunity to live and work in Australia, 德国, 日本和英国. I am proud of my role in developing our diverse and talented people.
I am passionate about working innovatively with patients and investigators to optimise their experience in our clinical trials so we can continue to deliver the next wave of life-changing medicines.
领导R的PMO&2019年全公司重组
2018年的《澳门葡京赌博游戏重新想象的未来》
Global 药物 Development 2014 and 2015
主要成就
2022年至今
2019 - 2022
2017 - 2019
Veeva ID: Z4-54718
编制日期:2023年5月